Ngā hua rapu kaituhi :: APM

1

<i>Fusarium</i> diversity associated with diseased cereals in China, with an updated phylogenomic assessment of the genus mā Shuangying Han, Mengmeng Wang, Zhiwei Ma, Mubashar Raza, Panfeng Zhao, Jianpin Liang, Min Gao, Y.J. Li, J.W. Wang, Die Hu, Lei Cai

I whakaputaina 2023

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
2

Computed Tomography–Quantified Body Composition Predicts Short-Term Outcomes After Gastrectomy in Gastric Cancer mā Yongwei Zhang, J.P. Wang, X.L. Wang, Hongyan Tian, T. Gao, Lijun Tang, Feng Tian, J.W. Wang, Heming Zheng, Labao Zhang, Xuejin Gao, Ganlin Li, Xinyun Wang

I whakaputaina 2018

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
3

Piperlongumine induces autophagy by targeting p38 signaling mā Y. Wang, J-W Wang, Xiong Xiao, Yuxi Shan, Boxin Xue, Guoqin Jiang, Qiongqiong He, J. Chen, H-G Xu, R-X Zhao, Kaitlin D. Werle, Rutao Cui, Jan C. Liang, Y-L Li, Z-X Xu

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
4

LKB1 reduces ROS-mediated cell damage via activation of p38 mā H-G Xu, Y-X Zhai, Jianfeng Chen, Yan Lu, J-W Wang, C-S Quan, R-X Zhao, Xiao Xiao, Qiongqiong He, Kaitlin D. Werle, H-G Kim, Richard D. Lopez, Rutao Cui, Jiyong Liang, Y-L Li, Z-X Xu

I whakaputaina 2014

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
5

Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes mā Yuanbo Liang, David F. Woodward, V.M. Guzman, C. Li, David F. Scott, J W Wang, L. A. Wheeler, Michael E. Garst, K Landsverk, George Sachs, Achim H.‐P. Krauss, Clive L. Cornell, Jose L. Martos, Simon N. Pettit, Hans Fliri

I whakaputaina 2008

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
6

$Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432$

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II... mā F. Wang, Xiaoli Wei, Fenggong Wang, Nong Xu, Lin Shen, Guanghai Dai, Xianglin Yuan, Y. Chen, S. Yang, Jiawei Shi, Xiang Hu, Xiandong Lin, Q.Y. Zhang, J. Feng, Yi Ba, Yanshi Liu, W. Li, Yongqian Shu, Yi Jiang, Quan Li, J.W. Wang, H. T. Wu, Hui Feng, Sheng Yao, Rui‐Hua Xu

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i: